Atalanta Therapeutics

Atalanta Therapeutics

  • Founded: 2018
  • Location: Boston, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Huntington's disease
  • Drug types: NEU, GEN
  • Lead product: Undisclosed
  • Product link: https://www.atalantatx.com/our-science-focus/
  • Funding: $110M A Jan 2021


atalantatx.com

linkedin.com

job board


Short description:

RNAi therapeutics

Drug notes:

Undisclosed programs RD Parkinson's, Alzheimer's, other neurodegenerative diseases

Long description:

Atalanta Therapeutics is using RNA interference (RNAi) technologies to find treatments for neurodegenerative diseases. RNAi is a natural process cells use to silence gene activity that can be employed as a strategy to target and silence disease-causing genes such as those driving neurological diseases. A major limitation of RNAi has been delivery of the technology to the central nervous system to target cells. Atalanta has developed their proprietary RNAi that uses their branched siRNA and enables RNAi to be deployed as a therapeutic approach throughout the brain and spinal cord. The branched siRNA has a common scaffold that supports delivery, but can also be customized at the nucleotide level to target different genes. Atalanta is currently focusing on Huntington’s disease.

Jobs:

Atalanta Therapeutics
Associate Scientist II, Oligonucleotide Chemistry
Boston, MA|39 days ago
Apply
Atalanta Therapeutics
Associate Scientist II/Senior Associate Scientist,...
Boston, MA|57 days ago
Atalanta Therapeutics
Associate Scientist I/II – siRNA Screening
Boston, MA|64 days ago
Atalanta Therapeutics
Senior Associate Scientist/Scientist I, Oligonucle...
Boston, MA|80 days ago


© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com